Short itright here at 93.96 ...if you have any money left to lose. I just added @ 93.75. This will bounce as the institutions, having sold to shake out retail investors, buy those shares back.
Well, PCYC from 2 to125 is the kind of investment we all dream about. After the fact it seems so simple: Ibrutinib is a game-changing drug, so buy and hold on. But along the way, there are many diversions, false alarms and feints which cause many to lose faith. I feel the same way about Xtandi: Just buy it and keep it. When it weakens, buy more. Continued good luck to you.
I added shares AH. But I wouldn't be surprised if they let it falter at the open to attract some shorts and then drive it higher.
Hey, this time his post only contains 2 outright lies. Still hasn't broken his old record of 6 lies in two sentences.
Well, Adam Feuerstein is tweeting blaming that "stupid PR person", when the whole mess is obviously a result of Feuerstein's sloppy 140 character journalism.
In today's tweets, Adam is (1)casually pretending the ADCOM briefing document was no real surprise to him, (2) blaming the whole fiasco on that "stupid PR person", and (3) continuing to throw out red herrings about osteosarcoma and excess something-or-other in the urine of patients which might result in a thumbs-down from ADCOM after all. It's everybody's fault but his. As for the poor retail investors who listened to him and sold at 26 ...nothing. Why doesn't he blame the CEO for soliciting his help in defusing the "strong investor reaction" to the ADCOM briefing documents? Because it never happened. He obviously tried to pump the PR person for news and the poor sap said, "Well, maybe I can get you an off-the-record chat with the CEO." The CEO, being no fool, nixed the idea and said that the documents could cause a strong reaction among investors. Adam misconstrued all of this to make it seem as if he had refused an opportunity to benefit from inside information. Some journalist.
Cramer's expertise in pharma stocks is illustrated by his AH rant advising everyone to sell CELG, since the approval of ONXX's carfilzomib for multiple myeloma would make Revlimid irrelevant. He dropped the stock about 7 bucks. I bought it, since I realized that carfilzomib was an adjunct to Revlimid, not a replacement. In fact, insofar as carfilzomib extended the lifespan of multiple myeloma patients, it would actually be good for Revlimid sales. Perhaps he was advised by his resident pharma guru, Feuerstein, in that one, too. If someone has something relevant to say about a stock, I would assume that it would take more than 140 characters.
Yes, the "They must know something" syndrome is very strong. I almost quadrupled my position over recent days because the Feuerstein tweet didn't make sense to me. And I was planning to add more shares once I'd had a look at the ADCOM briefing. When it opened so much higher, I decided to sit on my positions and wait - a mistake, in retrospect, since it added another 2 bucks. If I believed that there were substantial short positions in place, rather than just puts, I would have been more aggressive.
Well, I added some more shares at an average price of 98.40. My theory being that no large institution can bother with picking up the leavings of the sell-on-the-news retail shareholders. But I have no shame.
When the big funds want to add to a position, they will usually dunk it hard on the open on light volume and then walk it up slowly.
Shame on you, durango. There's such a thing as beating a dead horse. But bashing DNDN is like beating the skeleton of a dead horse.
Thanks, zacklabster. On one level I was hoping that they were being acquired. On another level, I'm glad they're not. I think this has a lot more room to run. Besides, who wants to get hit with another tax bill?
Yes, it was a perfect day: NPSP, PCYC, AVNR, MDVN, ...even RLYP. I was in such a good mood that I even tipped the guy that charged me $310 to unclog my kitchen sink drain. Then my check to the IRS cleared. Oh well, everyone has to get a piece of the action. Good luck to all.
Old news from May 30. However, the source, FT Alphaville, is the same one which broke the news of the competitive bidding for Intermune.